An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
MK-2870-010
NCT06312176
 Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Breast |
Dr. Katerine Marquis
Isabelle Gagnon
418-724-3000 poste 8029
|
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
MK-2870-012
NCT06393374
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Breast |
Dr. Marie-Claude Foley
Isabelle Gagnon
418-724-3000 poste 8029
|
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MK-1026-011 (BELLWAVE-011)
NCT06136559
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Chronic Lymphocytic Leukemia |
Dr. Samuel Nadeau
Marie-Eve Fournier
418-724-3000 poste 8029
|
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
PACIFIC-9
NCT05221840
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Non Small Cells - Lung |
Dr. Arnaud Blanchet-St-Pierre
Isabelle Gagnon
418-724-3000 poste 8029
|
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ? 50%) and Without Actionable Genomic Alterations
TROPION-Lung10
NCT06357533
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Non Small Cells - Lung |
Dr. Katerine Marquis
Isabelle Gagnon
418-724-3000 poste 8029
|
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
ARTEMIA
NCT06472245
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Non Small Cells - Lung |
Dr. Marie-Claude Foley
Isabelle Gagnon
418-724-3000 poste 8029
|
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
rechARge
NCT06764485
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Prostate |
Dr. Samuel Nadeau
Isabelle Gagnon
418-724-3000 poste 8029
|
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer.
TIGOS
NCT06646276
Recruiting
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Small Cells - Lung |
Dr. Samuel Nadeau
Marie-Eve Fournier
418-724-3000 poste 8029
|
Groupe d'étude en oncologie du Québec